Clinical Research of 18F-Alfatide Ⅱ PET/CT in Breast Cancer

Jiang Wu

Status and phase: Terminated; Phase 1

Conditions: Breast Cancer

Treatments: Drug: 18F-Alfatide Ⅱ PET/CT

Study type: Interventional

Funder types: Other

Identifiers

NCT02582801

Molecular Imaging

Details and patient eligibility

About

18F-Alfatide Ⅱ PET/CT in breast cancer patients

Full description

The investigators aim to assess the clinical application of 18F-Alfatide Ⅱ PET/CT in the diagnosis and treatment response monitoring of breast cancer.

Enrollment: 46 patients

Sex: Female

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• The patients have been suspected or diagnosed with breast cancer and they have not received any treatment; It must fulfill the ethical requirements and subjects have signed an informed consent.

Exclusion criteria

• Pregnancy or nursing mothers; Those patients accompanied by other serious diseases such as cardiac functional insufficiency, hepatic and renal function insufficiency.

Trial design

Primary purpose: Diagnostic

Allocation: Randomized

Interventional model: Single Group Assignment

Masking: Double Blind

---

46 participants in 2 patient groups

breast cancer

Experimental group

Description:

Perform 18F-Alfatide Ⅱ PET/CT in breast cancer patients

Treatment:

Drug: 18F-Alfatide Ⅱ PET/CT

benign breast lesions

Active Comparator group

Description:

Perform 18F-Alfatide Ⅱ PET/CT in patients with benign breast lesions

Treatment:

Drug: 18F-Alfatide Ⅱ PET/CT